TriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on Tuesday

TriSalus Life Sciences (NASDAQ:TLSI) will likely be announcing its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $10.44 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. The business had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $13.20 million. On average, analysts expect TriSalus Life Sciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

TriSalus Life Sciences Trading Up 3.6%

Shares of NASDAQ TLSI traded up $0.16 during midday trading on Tuesday, hitting $4.61. The company’s stock had a trading volume of 77,569 shares, compared to its average volume of 166,855. The business’s 50 day moving average is $4.41 and its two-hundred day moving average is $5.20. TriSalus Life Sciences has a 12-month low of $3.42 and a 12-month high of $7.95. The firm has a market cap of $282.64 million, a P/E ratio of -2.52 and a beta of 0.56.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TLSI shares. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of TriSalus Life Sciences in a report on Friday, April 10th. Finally, Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, March 6th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, TriSalus Life Sciences currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Insider Transactions at TriSalus Life Sciences

In related news, CEO Mary T. Szela sold 15,944 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $3.85, for a total value of $61,384.40. Following the transaction, the chief executive officer owned 752,987 shares of the company’s stock, valued at $2,898,999.95. This represents a 2.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 30,150 shares of company stock valued at $119,849 over the last quarter. 16.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TLSI. JPMorgan Chase & Co. grew its stake in TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in TriSalus Life Sciences in the second quarter worth approximately $47,000. Invesco Ltd. bought a new position in TriSalus Life Sciences in the fourth quarter worth approximately $72,000. Abel Hall LLC bought a new position in TriSalus Life Sciences in the fourth quarter worth approximately $73,000. Finally, Man Group plc bought a new position in TriSalus Life Sciences in the fourth quarter worth approximately $102,000. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.